PT-141

PT-141 is bremelanotide, and bremelanotide is a real medicine. The FDA approved it on 21 June 2019 as Vyleesi, a prescription autoinjector, for one use: premenopausal women with acquired, generalized hypoactive sexual desire disorder, meaning low desire that causes marked distress and is not explained by another medical or psychiatric condition, a relationship problem, or a drug. The label then names what it does not cover. It is not indicated for postmenopausal women. It is not indicated for men. It is not indicated to enhance sexual performance.

Inside that approval the results are clear and modest. Two identical 24-week placebo-controlled trials randomized 1,267 women. Desire scores rose and distress about low desire fell, both by statistically significant margins in both trials. The number of satisfying sexual events did not change: a mean change of 0.0 on the drug against 0.0 and minus 0.1 on placebo. Nausea hit 40 percent of women on the drug.

Outside it is where most of the market sits. PT-141 is sold mostly to men and as a performance enhancer, two uses the label excludes by name, in vials and nasal sprays that are not the approved product.

Bremelanotide is a synthetic cyclic heptapeptide: seven amino acids, closed into a ring, built to activate melanocortin receptors. PT-141 is its development code. Vyleesi is the approved product, a single-dose prefilled autoinjector manufactured for AMAG Pharmaceuticals.

It is unusual among sexual-function drugs because it does not target blood flow. It acts on receptors in the brain, and the label classifies it as a melanocortin receptor agonist rather than a vascular drug.

One Molecule, Several Receptors

Bremelanotide is not selective. The label lists its potency across the melanocortin family in this order: MC1R, MC4R, MC3R, MC5R, MC2R. At the doses studied, two of those matter most, and they explain both the intended effect and the most distinctive side effect.

MC4R is the desire arm. MC4R-expressing neurons sit in many parts of the central nervous system. An independent 2022 review describes bremelanotide acting on presynaptic MC4R to increase dopamine release in the nucleus accumbens, medial preoptic area, ventral tegmental area, arcuate nucleus and amygdala, regions involved in the motivational and appetitive side of sexual behavior.

MC1R is the skin arm. It is expressed on melanocytes, and activating it increases melanin. That is the direct route to the focal darkening of skin and gums described in the safety section.

What Is Known and What Is Not

The receptor targets are established. How activating them relieves low desire in women is not: the label states plainly that the mechanism by which Vyleesi improves HSDD is unknown. In men, the same review notes, MC3R and MC4R activation raises local nitric oxide and produces erections, which is the effect the early male studies measured.

The overreach here does not come from a lack of evidence. It comes from carrying an approval past its edges.

Treating desire as performance. The trials measured wanting sex and being bothered by not wanting it. Both moved. The outcome closest to what most buyers care about, how many satisfying sexual events occurred, did not move at all. Marketing that describes PT-141 as improving sexual performance is describing a use the label rules out in so many words.

Borrowing the approval for men. Bremelanotide was studied in men as a nasal spray and produced erections in a 2004 controlled study. That work did not lead to an approved male product. The approved label covers women only and states that it is not indicated in men. A man using PT-141 is relying on early-phase data for a use that regulators never approved.

Ignoring how often it is used. The skin risk is tied to frequency. Under the label's limits, focal darkening of the face, gums and breasts appeared in 1 percent of women in the phase 3 trials. In a separate study where the drug was given every day, 38 percent developed it, and another 14 percent of those who continued developed new patches. People with darker skin were more likely to be affected, and the pigment did not clear in everyone after stopping. A prescription carries a frequency limit for that reason. A vial does not.

Reading the 2004 male study as proof of safety in men. It was an early-phase pharmacology study. It did not establish long-term safety in any male population.

The safety profile is well described, and tolerability is the main problem.

In the pooled phase 3 trials, nausea affected 40.0 percent of women on bremelanotide against 1.3 percent on placebo. It was most likely after the first dose, reported by 21 percent, then fell to about 3 percent after later doses. Thirteen percent of women took anti-nausea medication. Flushing affected 20.3 percent against 0.3 percent, injection site reactions 13.2 against 8.4, and headache 11.3 against 1.9. Overall, 18 percent stopped the drug because of adverse reactions, against 2 percent on placebo.

Each dose raises blood pressure briefly, by up to 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate falling by up to 5 beats per minute. Values usually return to baseline within 12 hours. The label contraindicates bremelanotide in uncontrolled hypertension and known cardiovascular disease.

Other label warnings: focal hyperpigmentation, covered above; one case of acute hepatitis in the extension phase where a role for the drug could not be excluded; slowed gastric emptying that can blunt oral medicines; and a marked reduction in oral naltrexone exposure, enough that the two should not be combined.

All of these rates come from the approved product, taken by screened women under medical supervision.

Split PT-141 into two questions and the answers are unusually clean.

On-label: for a premenopausal woman with diagnosed acquired, generalized HSDD, bremelanotide is a proven option with a known effect size. It raised desire scores and lowered distress in two large trials, and it did not increase the number of satisfying sexual events. Nausea is likely, especially at first, and nearly one woman in five on the drug stopped because of side effects. Whether that trade is worth it is a decision for her and her prescriber, and many reasonable people will land on either side.

Off-label: for men, postmenopausal women, and anyone hoping for better sexual performance, the trials that produced the approval do not apply. The male data stops at an early study, and the approval excludes performance enhancement by name.

The most useful thing to carry away is the gap itself. An FDA approval is precise about who, for what, and in what product. PT-141 shows how far marketing can travel from that precision while still quoting it.

Not approved for men. The Vyleesi label states that it is not indicated for HSDD in men. The male development work ended at early-phase studies of a nasal spray.

Not approved to enhance sexual performance. That exclusion is written into the label's Limitations of Use, and the trials found no increase in satisfying sexual events.

Not approved after menopause. The indication is limited to premenopausal women, and the label excludes postmenopausal women by name.

Not the approved product when it comes as a vial or a nasal spray. Vyleesi is a prefilled autoinjector. Compounded and research-chemical versions have not been reviewed by the FDA for safety, effectiveness or quality.

Not on the WADA Prohibited List. Bremelanotide is not named, and S0 does not apply because the substance holds regulatory approval. That status describes the substance, not the quality of whatever is in an unregulated vial.

PT-141 is the clearest example I have of an approval being used as a sales pitch for something the approval explicitly ruled out.

I want to be fair to the drug, because the drug earned it. Two well-run phase 3 trials, more than twelve hundred women, both primary endpoints met in both trials, published side effects and all. For the women it was approved for, it is a legitimate treatment with a known, modest benefit and a known cost in nausea. I am not going to talk about it in the cautious tone I use for compounds with nothing but rodent data behind them.

But I am also going to be exact about what it did. It raised desire and lowered distress. It did not produce more satisfying sex than placebo. It was never approved for men. It is not approved to improve performance, and the label says so in a sentence anyone can read. When a product page leans on the words FDA-approved to sell PT-141 to a man looking for an edge, it is citing the document that excludes him.

I will not publish doses or tell anyone how to get it. If low desire is genuinely distressing you, that is a conversation worth having with a clinician, and this is one of the few compounds in this library where that conversation can end in a real prescription.